CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Remote pulmonary rehabilitationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Intelligence-based Remote Pulmonary Rehabilitation and Efficacy Among Discharged COVID-19 Patients

The noval coronavirus disease 2019 (COVID-19) would cause physical and psychological dysfunctions in infected patients. We expect that an intelligence-based remote pulmonary rehabilitation scheme could improve patients' health status after hospital discharge. The intelligence-based remote pulmonary rehabilitation program is designed in a real-world and prospective manner, aiming to evaluate the efficacy of rehabilitation among 200 patients in the epicenter of China (Wuhan City) according to their varied adherence. An eight-week rehabilitation scheme, including two weeks for physicians and physiotherapists remotely guided training, and six weeks for patient self-management, will be addressed. The primary outcome of current study is six-minute walking distance and lung function, and secondly respiratory muscle strength, physical fitness assessment, symptoms and quality of life, etc. will also be assessed. Recruited patients will be followed up at week 2, 4, 8 after enrollment and at month 1, 3, 6, 12 after the rehabilitation training completed, respectively. The study has been approved by the ethics committee of China-Japan Friendship Hospital and three participating centers in Wuhan City.

NCT04368793 COVID-2019 Pneumonia Pulmonary Rehabilitation Behavioral: Remote pulmonary rehabilitation
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Walking distance within six minutes

Measure: Six-minute walking distance (6MWD)

Time: One year

Description: Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), etc.

Measure: Pulmonary function

Time: One year

Secondary Outcomes

Description: Maximal inspiratory pressure, maximal expiratory pressure, etc.

Measure: Respiratory muscle strength

Time: One year

Description: Two-minute walking test, short physical performance battery, grip strength of both upper limbs, knee extension strength of both lower limbs, etc.

Measure: Physical fitness assessment

Time: One year

Description: Modified British Medical Research Council (mMRC) dyspnea scale, etc.

Measure: Symptom

Time: One year

Description: Self-training depression scale (SDS) and self-rating anxiety scale (SAS)

Measure: Psychological evaluation

Time: One year

Description: 36-item short-form health survey (SF-36), etc.

Measure: Quality of life

Time: One year

Description: International physical activity questionnaire (IPAQ)

Measure: Physical activity

Time: One year

Description: Proportions of returning to routine work and normal life

Measure: Proportion of returning to society

Time: One year


Related HPO nodes (Using clinical trials)